EPHA2 and lung carcinoma: CARTs targeting fibroblast activation protein-α (FAP), a tumor stromal-associated antigen expressed by CAFs, delivered in combination with an EphA2-targeting CAR population was shown to control the tumor growth in an A549 lung cancer model more effectively than either agent alone (37).